Matinas biopharma reports first quarter 2021 financial results and operational highlights

– enrollment continues in second cohort of enact study of mat2203 (oral amphotericin b) in cryptococcal meningitis; data and safety monitoring board (dsmb) evaluation of safety and efficacy data from second cohort anticipated q3 2021 –
MTNB Ratings Summary
MTNB Quant Ranking